In vitro cell response to chemotherapeutic agents, to personalize ovarian cancer treatment. Report of two cases;Potencial herramienta en la personalización del tratamiento oncológico. Casos clínicos

Revista Medica de Chile

Volumn 141, Issue 5, 2013, Pages 669-673

  Ibáñez C , Carolina ^a   Garrido S , Marcelo ^a   Medina, Lidia ^a   Kato, Sumie ^a   Bravo, María Loreto ^a,d   González, Pamela ^a   Oliva, Barbara ^a   Pizarro, Javier ^b   Bustamante, Eva ^c   Brañes, Jorge ^a   Cuello, Mauricio ^a   Owen, Gareth I ^a,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^c Centro Oncológico Fundación Arturo López Pérez   (Chile)

^d Biomedical Research Consortium of Chile   (Chile)

Author keywords

Antineoplastic protocols; Ascitic fluid; Ovarian neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD; CASE REPORT; DISEASE FREE SURVIVAL; FEMALE; HUMAN; OVARY TUMOR; PERSONALIZED MEDICINE; REMISSION; TUMOR CELL CULTURE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; OVARIAN NEOPLASMS; REMISSION INDUCTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84883186357     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872013000500017     Document Type: Article

References (14)

1. Donoso, E. Cambio del perfil epidemiológico y demográfico determina un mayor riesgo de cáncer ginecológico en la mujer chilena. Rev Chil Obstet Ginecol 2012; 77 (4): 247-8.
2. Sieguel R, Naishadham D, Jemal A. Cancer Statistics. CA Cancer J Clin 2012; 62: 10-29.
3. Goff B, Mandel L, Muntz H, Melancon C. Ovarian Carcinoma Diagnosisresults of a National Ovarian Cancer Survey. Cancer 2000; 15: 2068-75.
4. Pignata S, Cannella L, Leopardo D, Pisano C, Bruni G, Facchini G. Chemotherapy in epithelial ovarian cancer. Cancer Letters 2011; 303: 73-83.
5. Mutch DG. Surgical management of ovarian cancer. Semin Oncol 2002; 29 (1 Suppl 1): 3-8.
6. Jelovac D, Armstrong D, Recent Progress in the Diagnosis and Treatment of ovarian Cancer. CA Cancer J Clin 2011; 61: 183-203.
7. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature, 2011; 474: 609-15.
8. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S; TCA Ovarian Cancer Trial Group. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 2007; 18 (9): 1093-101.
9. Shink JC, Copeland LJ. Point: chemosensitivity assays have a role in the management of recurrent ovarian cancer. J Natl Compr Cancer Netw 2011; 1: 115-20.
10. Herzog TJ, Krivak TC, Fader AN, Coleman RL. Chemosensitivity tetsing with ChemoxFx and overall survival in primary ovarían Cancer. Am J Obstet Gynecol 2010; 203: 68. e1-6.
11. Sadarangani A, Kato S, Espinoza N, Lange S, Llados C, Espinosa M, et al., TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis. 2007; 12 (1): 73-85.
12. Hunz M, Jetter A, Warm M, Pantke E, Tuscher M, Hempel G, et al. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther. 2007; 81 (5): 659-68.
13. Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, et al. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol. 1996; 39 (1-2): 131-7.
14. Celio LA, DiGregorio GJ, Ruch E, Pace J, Piraino AJ. Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. Eur J Clin Pharmacol 1983; 24 (2): 261-6.